Sort by
Refine Your Search
-
Overview The Laboratory for Cellular Metabolism and Metabolic Regulation (Fendt Lab) is a young and dynamic team of researchers performing cutting edge cancer metabolism research with special focus
-
, ultimately triggering neuroinflammation. The PhD student will help uncover the molecular and cellular pathways linking the allergic gut to the inflamed brain, and how these pathways shape disease risk later in
-
well as the available public data suggest mechanisms involving genetic, epigenetic and chromatin organisation factors governing the cell-type specific response to ARS mutations. Therefore, an integrative genome-wide cis
-
-research teams with a broad range of expertise, access to state-of-the-art technology and facilities ((epi-)genomics, transcriptomics, (single-cell) sequencing, bioinformatics, etc), institutional training
-
that combines structural biology, biochemistry, and cell biology. The lab is particularly focused on biomolecular interactions, characterizing regulatory complexes, and developing novel therapeutic
-
, and poor prognosis of CRC. Adenocarcinomas also overexpress transmembrane mucins to exploit their role in promoting tumour cell death resistance. Furthermore, mucins undergo extensive splicing. Mucins
-
(genome sequencing), bioinformatics and single-cell (microscopy, microfluidics, FACS) analyses of E. coli bacteria and will be centred around the following themes: Pathways involved in robustness against de
-
the imec-Vision Lab (image reconstruction, processing, and analysis), the Bio-Imaging Lab (preclinical neuro-MRI), and the Laboratory of Cell Biology and Histology (cell biology and advanced microscopy
-
towards cancer and has been linked to initiation, progression, and poor prognosis of colorectal cancer. Adenocarcinomas also overexpress transmembrane mucins to exploit their role in promoting tumour cell
-
the preparation and defence of a PhD thesis in the field of Medical Sciences. More specific, you will work on the validation of predictive peptide biomarkers to classify non-small cell lung cancer (NSCLC) patients